Davis Smith*
Department of Clinical Pharmacy, Johns Hopkins University, United States
Received: 01-Mar-2025, Manuscript No. dd-25-171101; Editor Assigned: 04-Mar-2025, Pre QC No. dd-25- 171101; Reviewed: 15-Mar-2025, QC No. dd-25-171101; Revised: 20-Mar- 2025, Manuscript No. dd-25-171101; Published: 29-Mar-2025, DOI:10.4172/resrevdrugdeliv.9.1.001
Citation: Davis Smith, mRNA Drug Delivery: Unlocking a New Era in Medicine. Res Rev Drug Deliv. 2025;9.005.
Copyright: © 2025 Davis Smith, this is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and sources are credited.
Visit for more related articles at Research & Reviews: Drug Delivery
Messenger RNA (mRNA) technology has emerged as a groundbreaking approach in modern medicine, gaining global recognition during the COVID-19 pandemic with the rapid development of mRNA vaccines. Unlike traditional therapies that rely on proteins or small molecules, mRNA drugs use the body’s own cellular machinery to produce therapeutic proteins [1]. This approach holds promise not only for infectious disease prevention but also for cancer treatment, genetic disorders, and regenerative medicine. However, the success of mRNA therapies depends heavily on the efficiency and safety of their delivery systems, making mRNA drug delivery a central focus of biomedical research [2].
Delivering mRNA into cells is challenging because the molecule is inherently unstable and can be rapidly degraded by enzymes in the body. Furthermore, naked mRNA cannot easily cross cell membranes due to its large size and negative charge. To overcome these hurdles, scientists have developed sophisticated delivery platforms [3].
One of the most widely used delivery methods is lipid nanoparticles (LNPs). LNPs protect mRNA from enzymatic degradation, facilitate cellular uptake, and enable controlled release inside the target cells. This technology was pivotal in the success of COVID-19 mRNA vaccines. Researchers are continually refining LNP formulations to improve stability, tissue targeting, and reduce side effects such as inflammation [4].
Polymeric nanoparticles and peptide-based carriers are also being explored as alternatives to LNPs. These platforms can be engineered for specific applications, such as targeting cancer cells or delivering mRNA across biological barriers like the blood-brain barrier. In addition, viral vectors, while less common due to safety concerns, provide another option for efficient mRNA transport.
Another key area of innovation is targeted delivery. Current mRNA therapies mostly target muscle or liver tissue, but future breakthroughs may allow delivery to the heart, brain, or lungs. Targeted delivery could revolutionize the treatment of genetic diseases, enabling the replacement of missing or defective proteins in specific tissues [5].
Despite these advances, challenges remain. Immune system activation can sometimes reduce the effectiveness of repeated dosing. Manufacturing and storage are also critical issues, as mRNA drugs often require ultra-cold conditions. Addressing these challenges will be crucial for making mRNA therapies widely accessible and affordable.
mRNA drug delivery has transformed the landscape of modern therapeutics, offering rapid, flexible, and powerful tools against diseases. With innovations in nanoparticle systems and targeted delivery, the potential applications of mRNA extend far beyond vaccines to cancer immunotherapy, protein replacement, and regenerative medicine. However, the path forward requires continued research to improve stability, targeting precision, and scalability of delivery systems. If these challenges are met, mRNA therapies may become a cornerstone of personalized medicine, ushering in a future where treatments are faster to develop, more effective, and tailored to individual patients [6].
Menu